NASDAQ: RANI - Rani Therapeutics Holdings, Inc.

Yield per half year: -70.01%
Sector: Healthcare

Share chart Rani Therapeutics Holdings, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies.

More details
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.000979
EBITDA -0.0261
Число акций ао 0.02551 млрд
P/S 4296.54
P/BV -43.53
EV/EBITDA -165.09
Цена ао 3.18
ISIN US7530181004
Сайт https://www.ranitherapeutics.com
Валюта usd
IPO date 2021-07-30
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: 0% (2.12)
Change price per week: -9.79% (2.35)
Change price per month: -10.55% (2.37)
Change price per 3 month: -37.09% (3.37)
Change price per half year: -70.01% (7.07)
Change price per year: +5.47% (2.01)
Change price per 3 year: -86.82% (16.09)
Change price per year to date: +5.47% (2.01)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 3.31 5
P/E 0 0
EV/EBITDA -1.65 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -58.65 0
ROE, % -264.03 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.4611 10
Total: 7.8

Growth impulse

Title Value Grade
Yield Revenue, % 175.79 10
Yield Ebitda, % 150.1 10
Yield EPS, % -6.2 0
Total: 6.6
More

Institutions Volume Share, %
Vanguard Group Inc 668347 2.57
Nan Fung Group Holdings Limited 493584 1.9
United Services Automobile Association 481300 1.85
Alphabet Inc. 448492 1.72
Bank of America Corporation 114259 0.44
Geode Capital Management, LLC 113629 0.44
Blackrock Inc. 63583 0.24
Lasry, Marc 62887 0.24
Alpha Square Group S, LLC 58946 0.23
King Luther Capital Management 56129 0.22

ETF Share, % Profitability for 1 year, % Dividends, %
Dimensional International Core Equity 2 ETF 0.00033 12.593206296603 3.69996
Dimensional International Small Cap ETF 0.00065 13.318681318681 3.34747
Dimensional International Small Cap Value ETF 0.00059 13.61043194784 4.55441



Head Job title Payment Year of birth
Mr. Mir A. Imran Executive Chairman 80k 1956 (68 years)
Mr. Talat Imran CEO & Director 450k 1982 (42 years)
Mr. Svai S. Sanford Chief Financial Officer 416k 1970 (54 years)
Dr. Mir Hashim Chief Scientific Officer 416k 1960 (64 years)
Mr. Eric Groen General Counsel N/A 1971 (53 years)
Ms. Bella Vazquez Vice President of Human Resources N/A
Ms. Kate McKinley M.B.A. Chief Business Officer N/A 1977 (47 years)
Ms. Arvinder Dhalla Vice President of Clinical Development N/A

Address: United States, San Jose. CA, 2051 Ringwood Avenue - open in Google maps, open in Yandex maps
Website: https://www.ranitherapeutics.com